RxDoctor Payments Data

Athena Papas

General Practice · Boston, MANPI 1164431573

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,918 of the $6,967 with a category attached, or 99.3%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 81.7% of it on its own, with 1 other manufacturer making up the rest. Among general practice clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,967in general payments, 2019–2025

Across 5 payments — averaging $1393.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • Biogen$1K
$1,382,524in research payments, 2019–2025

Across 63 payments — averaging $21,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$931K
  • Amgen$388K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
  • Biogen$17K
  • Solventum Corporation$14K
  • Gilead$11K
  • plus $672 from 1 others

What the payments were for

  • Consulting fees$6,91899%
  • Food & beverage$491%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,967 in reported general payments places this provider in the 95th percentile of 2,391 general practice providers in Massachusetts.

See all general practice providers in Massachusetts

Other general practice in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →